BioHarvest Sciences (BHST)
NASDAQ:BHST
Want to see BHST full AI Analyst Report?
BHST Stock Chart & Stats
$11.28
--
Market closed
$11.28
--
Day’s Range― - ―
52-Week Range$3.57 - $12.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)78.84K
Market Cap
$87.50M
Enterprise Value$64.13M
Total Cash (Recent Filing)$19.17M
Total Debt (Recent Filing)$16.42M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 31, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding22,667,843
10 Day Avg. Volume86,360
30 Day Avg. Volume78,844
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.75
Price to Sales (P/S)2.77
P/FCF Ratio-9.97
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue1.82
Enterprise Value/Gross Profit3.07
Enterprise Value/Ebitda-9.60
Forecast
1Y Price Target
$12.00Price Target Upside6.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.33
Revenue Forecast (FY)$44.55M
Bulls Say, Bears Say
Bulls Say
Brand Leadership And Consumer DemandAnalyst points to VINIA achieving market-leading status among resveratrol brands in the U.S., reinforcing brand strength and consumer demand that can support repeat sales and category leadership.
Revenue Growth DriversAnalyst cites meaningful momentum in both the direct-to-consumer nutraceutical business and the contract development services as main revenue growth drivers, indicating expanding sales channels and diversified revenue streams.
Technology Validation And Scalable ManufacturingAnalyst emphasizes the CDMO technical milestone of producing a stable cell culture for a rare fragrance plant and the botanical synthesis platform's ability to replicate plant cells at large scale without traditional harvesting, validating scalable, sustainable production for complex molecules and contract services.
Bears Say
Operational And Geopolitical RisksAnalyst warns of the potential for failure to achieve expected cost leverage, partnerships stalling, and geopolitical unrest where operations are centered, any of which could disrupt production and contract relationships.
Product Commercialization RiskAnalyst highlights the risk that new products may fail to gain commercial acceptance, which could limit revenue growth despite technological advances.
Profitability ChallengesAnalyst notes that the company continues to record operating and net losses, reflecting ongoing profitability challenges that need to be resolved.
BioHarvest Sciences News
BHST FAQ
What was BioHarvest Sciences’s price range in the past 12 months?
BioHarvest Sciences lowest stock price was $3.57 and its highest was $12.80 in the past 12 months.
What is BioHarvest Sciences’s market cap?
BioHarvest Sciences’s market cap is $87.50M.
When is BioHarvest Sciences’s upcoming earnings report date?
BioHarvest Sciences’s upcoming earnings report date is Aug 31, 2026 which is in 90 days.
How were BioHarvest Sciences’s earnings last quarter?
Currently, no data Available
Is BioHarvest Sciences overvalued?
According to Wall Street analysts BioHarvest Sciences’s price is currently Undervalued.
Does BioHarvest Sciences pay dividends?
BioHarvest Sciences does not currently pay dividends.
What is BioHarvest Sciences’s EPS estimate?
BioHarvest Sciences’s EPS estimate is -0.12.
How many shares outstanding does BioHarvest Sciences have?
BioHarvest Sciences has 22,667,843 shares outstanding.
What happened to BioHarvest Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioHarvest Sciences?
Currently, no hedge funds are holding shares in BHST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioHarvest Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (6.38% Upside)
$12.00 (6.38% Upside)
Blogger Sentiment
Neutral
BHST Sentiment 50%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.22%
12-Months-Change
Fundamentals
Return on Equity
-88.01%
Trailing 12-Months
Asset Growth
71.33%
Trailing 12-Months
Company Description
BioHarvest Sciences
BioHarvest Sciences (BHST) is a biotechnology company specializing in the development and commercialization of innovative plant-based products for the health and wellness sectors. The company leverages its proprietary technology to produce high-quality, bioavailable compounds from various plants, targeting markets such as dietary supplements, nutraceuticals, and functional foods. With a focus on sustainability and scalability, BioHarvest aims to meet the growing consumer demand for natural health solutions.
BHST Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid technological and commercial progress — notable CDMO milestones (Stage 1 completions, a $1.2M Stage 2 fragrance contract with 20% retained ownership, and Saffron Stage 1 advancement), stronger cash position, and clear D2C product traction (VINIA Blood Flow Hydration, strong reviews, active users). However, near-term financials show continued net losses, increased operating and marketing spend, and a deliberate D2C marketing reset that temporarily depressed revenue. Execution risks remain around manufacturing capacity timing (new facility target H2 2027), potential future capital needs, and early-stage validation for novel assets. Overall the positives (milestones, cash build, pipeline, product traction and reiterated guidance) outweigh the short-term headwinds and uncertainties, but successful execution over the next quarters — especially H2 2026–2027 — will be critical to realize the opportunities.View all BHST earnings summariesBHST Stock 12 Month Forecast
Average Price Target
$12.00
▲(6.38% Upside)
Technical Analysis
Ownership Overview
0.08% Insiders
0.05% Mutual Funds
6.94% Other Institutional Investors
92.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---